← FDA DRUG APPROVALS

FDA NDA · NDA215092

OMLONTI

omidenepag isopropyl

Sponsor: OCUVEX THERAP

APPLICATION
NDA215092
TYPE
NDA
ORIGINAL APPROVAL
2022-09-22
LATEST ACTION
2022-09-22
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

OMLONTI · ReferencePrescription
OMIDENEPAG ISOPROPYL 0.002% · SOLUTION · OPHTHALMIC

Approval history

2022-09-22Type 1 - New Molecular Entity · Original · standardLabelAP
2022-09-22UNKNOWN · Supplement 1 · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →